Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

Authors: Zsuzsanna Varga, Aurelia Noske, Constanze Ramach, Barbara Padberg, Holger Moch

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The gold standard of HER2 status assessment in breast cancer is still debated. Immunohistochemistry (IHC) and in-situ technology as fluorescent-labeled methodology (FISH) can be influenced by pre-analytical factors, assay-conditions and interpretation of test results. We retrospectively conducted this quality control study and analyzed HER2 test results in breast cancer within the routine diagnostic service in a single institution over a period of 12 years. We addressed the question how stable and concordant IHC and FISH methods are and whether HER2 positivity rate has changed over this period.

Methods

Data of 7714 consecutive HER2-FISH-assays in a period of 12 years (2001–2012) on breast cancer biopsies and excision specimens were retrospectively analyzed. From 2001 to 2004, FISH tests were performed from all cases with IHC score 3+ and 2+ (and in some tumors with IHC score 1+ and 0). From 2005–2010, HER2 status was only determined by FISH. From 2011–2012, all breast carcinomas were analyzed by both IHC and FISH. Scoring and cut-off-definition were done according to time-current ASCO-CAP and FDA-guidelines.

Results

Between 2001–2004, IHC score 3+ was diagnosed in 22% of cases, 69% of these 3+ cases were amplified by FISH. 6% of IHC score 0/1+ cases were amplified by FISH. There was a mean amplification rate of 15.8% (range 13 -19%) using FISH only HER2-assays (2005–2010). Starting 2008, a slight drop in the amplification rate from 17% to 14% was noticed due to the modified ASCO-criteria in 2007. From 2011–2012, 12% of cases were 3+ by IHC, 84% of them were amplified by FISH. Less than 1% of IHC score 0/1+ cases were amplified by FISH. Concordance between FISH and IHC increased from 83% to 97%.

Conclusions

Our quality control study demonstrates that HER2 positivity rate remained stable by FISH-technology but showed a significant variation by IHC over the analyzed 12 years. Improvement in concordance rate was due to standardization of pre-analytical factors, scoring and interpretation.
Appendix
Available only for authorised users
Literature
1.
Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001, 19 (2): 354-363.PubMed
2.
Moelans CB, de Weger RA, Van der Wall E, van Diest PJ: Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol. 2011, 80 (3): 380-392. 10.1016/j.critrevonc.2010.12.005.CrossRefPubMed
3.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25 (1): 118-145.CrossRefPubMed
4.
Dekker TJ, Smit VT, Hooijer GK, Van de Vijver MJ, Mesker WE, Tollenaar RA, Nortier JW, Kroep JR: Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol. 2013, 24 (4): 931-937. 10.1093/annonc/mds599.CrossRefPubMed
5.
Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008, 21 (Suppl 2): S8-S15.CrossRefPubMed
6.
Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009, 27 (8): 1323-1333. 10.1200/JCO.2007.14.8197.CrossRefPubMed
7.
Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, Cummings M, Farshid G, Field A, Morey A, et al: Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast. 2003, 12 (2): 92-98. 10.1016/S0960-9776(02)00273-4.CrossRefPubMed
8.
Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M: Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003, 16 (2): 173-182. 10.1097/01.MP.0000052102.90815.82.CrossRefPubMed
9.
Kovacs A, Stenman G: HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry. Pathol Res Pract. 2010, 206 (1): 39-42. 10.1016/j.prp.2009.08.003.CrossRefPubMed
10.
Blank PR, Schwenkglenks M, Moch H, Szucs TD: Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat. 2010, 124 (2): 497-507. 10.1007/s10549-010-0862-7.CrossRefPubMed
11.
Parkinson B, Pearson SA, Viney R: Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. Eur J Health Econ. 2013,  -February, 1618-7601, 10.1007/s10198-013-0459-2
12.
Hicks DG, Tubbs RR: Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol. 2005, 36 (3): 250-261. 10.1016/j.humpath.2004.11.010.CrossRefPubMed
13.
Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, et al: Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol. 2007, 16 (4): 207-210. 10.1097/PDM.0b013e318064c72a.CrossRefPubMed
14.
Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, Fox SB, Francis GD, Waite B, McCue G, et al: Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Res Treat. 2012, 134 (2): 617-624. 10.1007/s10549-012-2093-6.CrossRefPubMedPubMedCentral
15.
Pathmanathan N, Provan PJ, Mahajan H, Hall G, Byth K, Bilous AM, Balleine RL: Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. Breast. 2012, 21 (6): 724-729. 10.1016/j.breast.2012.09.001.CrossRefPubMed
16.
Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK: High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol. 2012, 25 (10): 1326-1332. 10.1038/modpathol.2012.93.CrossRefPubMed
17.
Bulliard JL, Ducros C, Jemelin C, Arzel B, Fioretta G, Levi F: Effectiveness of organised versus opportunistic mammography screening. Ann Oncol. 2009, 20 (7): 1199-1202. 10.1093/annonc/mdn770.CrossRefPubMed
18.
Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT: Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med. 2009, 133 (5): 775-780.PubMed
19.
Atkinson R, Mollerup J, Laenkholm AV, Verardo M, Hawes D, Commins D, Engvad B, Correa A, Ehlers CC, Nielsen KV: Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med. 2011, 135 (8): 1010-1016. 10.5858/2010-0462-OAR.CrossRefPubMed
20.
Babic A, Loftin IR, Stanislaw S, Wang M, Miller R, Warren SM, Zhang W, Lau A, Miller M, Wu P, et al: The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods. 2010, 52 (4): 287-300. 10.1016/j.ymeth.2010.08.012.CrossRefPubMed
21.
Burandt E, Sauter G, Burandt E, Sauter G: HER2 ASCO guidelines. The answer to everything?. Pathologe. 2010, 31 (Suppl 2): 285-291.CrossRefPubMed
22.
Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, Rao N, Lu DY, Apple SK: Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 2011, 136 (5): 754-761. 10.1309/AJCP99WZGBPKCXOQ.CrossRefPubMed
23.
Bartlett J, Mallon E, Cooke T: The clinical evaluation of HER-2 status: which test to use?. J Pathol. 2003, 199 (4): 411-417. 10.1002/path.1354.CrossRefPubMed
24.
Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG: Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001, 195 (4): 422-428. 10.1002/path.971.CrossRefPubMed
25.
Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008, 21 (10): 1271-1277. 10.1038/modpathol.2008.83.CrossRefPubMed
26.
Martin V, Camponovo A, Ghisletta M, Bongiovanni M, Mazzucchelli L: Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab. Patholog Res Int. 2012, 2012: 261857-PubMedPubMedCentral
27.
Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson B, Mallon E, Lee PB: Recommendations for HER2 testing in the UK. J Clin Pathol. 2000, 53 (12): 890-892. 10.1136/jcp.53.12.890.CrossRefPubMedPubMedCentral
28.
Schnitt SJ, Jacobs TW: Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol. 2001, 116 (6): 806-810. 10.1309/WMN8-VTR5-DUGF-X12L.CrossRefPubMed
29.
Arnould L, Roger P, Macgrogan G, Chenard MP, Balaton A, Beauclair S, Penault-Llorca F: Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). Mod Pathol. 2012, 25 (5): 675-682. 10.1038/modpathol.2011.201.CrossRefPubMed
30.
Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Connolly Y, Campbell F, O'Grady A, Barnett S, et al: External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme. Am J Clin Pathol. 2009, 131 (1): 106-111. 10.1309/AJCPLN78ZQXEMNMA.CrossRefPubMed
31.
Choritz H, Busche G, Kreipe H: Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch. 2011, 459 (3): 283-289. 10.1007/s00428-011-1132-8.CrossRefPubMedPubMedCentral
32.
Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Ruschoff J, Gutjahr T, Habben K, van de Vijver MJ: Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol. 2007, 20 (5): 584-591. 10.1038/modpathol.3800774.CrossRefPubMed
33.
Hardy LB, Fitzgibbons PL, Goldsmith JD, Eisen RN, Beasley MB, Souers RJ, Nakhleh RE: Immunohistochemistry validation procedures and practices: a College of American Pathologists survey of 727 laboratories. Arch Pathol Lab Med. 2013, 137 (1): 19-25. 10.5858/arpa.2011-0676-CP.CrossRefPubMed
34.
Umemura S, Osamura RY, Akiyama F, Honma K, Kurosumi M, Sasano H, Toyoshima S, Tsuda H, Ruschoff J, Sakamoto G: What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard. Am J Clin Pathol. 2008, 130 (6): 883-891. 10.1309/AJCP5UUMFMA5ZKII.CrossRefPubMed
35.
Vani K, Sompuram SR, Fitzgibbons P, Bogen SA: National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. Arch Pathol Lab Med. 2008, 132 (2): 211-216.PubMed
36.
Moelans CB, De Weger RA, Van Diest PJ: Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter. Clin Cancer Res. 2010, 16 (24): 6177-6178. 10.1158/1078-0432.CCR-10-0773. author replyCrossRefPubMed
37.
Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME: Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009, 133 (4): 611-612.PubMed
38.
Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A, Kradolfer D, Bosshard G, Jochum W, Moch H, Ohlschlegel C: Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res Treat. 2012, 132 (3): 925-935. 10.1007/s10549-011-1642-8.CrossRefPubMed
Metadata
Title
Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study
Authors
Zsuzsanna Varga
Aurelia Noske
Constanze Ramach
Barbara Padberg
Holger Moch
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-615

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Survival of patients with operable breast cancer (Stages I-III) at a Brazilian public hospital - a closer look into cause-specific mortality

Research article

Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort study

Research article

Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil

Research article

Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival

Study protocol

Study protocol: rehabilitation including social and physical activity and education in children and teenagers with cancer (RESPECT)

Research article

Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits